LOMOTIL (diphenoxylate hydrochloride and atropine sulfate) by Pfizer is clinical pharmacology diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. First approved in 1960.
Drug data last refreshed 18h ago · AI intelligence enriched 6d ago
LOMOTIL is an oral antidiarrheal combination containing diphenoxylate hydrochloride and atropine sulfate, approved in 1960. It reduces diarrhea by enhancing intestinal segmentation and prolonging gastrointestinal transit time through direct effects on bowel smooth muscle. The product is indicated for symptomatic relief of acute and chronic diarrhea.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation or transition planning.
CLINICAL PHARMACOLOGY Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. After a 5 mg oral dose of carbon-14 labeled diphenoxylate hydrochloride in ethanolic solution…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LOMOTIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LOMOTIL offers limited career growth opportunity due to its mature, LOE-approaching lifecycle and minimal linked job openings. Roles available are primarily in brand management and sales optimization focused on defending market share against generics rather than growth initiatives.